The University of Southampton
University of Southampton Institutional Repository

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.

TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Background: MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemotherapy showed activity in non-small-cell lung cancer and the baseline value of CD16, CD56, CD69 triple-positive activated lymphocytes (TrPAL) was shown to be potentially predictive of TG4010 efficacy. In this phase 2b part of the phase 2b/3 TIME trial, we further assess TG4010 in combination with first-line chemotherapy and use of the TrPAL biomarker in this setting.

Methods: In this phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, we recruited previously untreated patients aged 18 years or older with stage IV non-small-cell lung cancer without a known activating EGFR mutation and with MUC1 expression in at least 50% of tumoural cells. Patients were randomly allocated (1:1) by an external service provider to subcutaneous injections of 108 plaque-forming units of TG4010 or placebo from the beginning of chemotherapy every week for 6 weeks and then every 3 weeks up to progression, discontinuation for any reason, or toxic effects, stratified according to baseline value of TrPAL (? or > the upper limit of normal [ULN]) and, in addition, a dynamic minimisation procedure was used, taking into account chemotherapy regimen, histology, addition or not of bevacizumab, performance status, and centre. Patients, site staff, monitors, the study funder, data managers, and the statistician were masked to treatment identity. The primary endpoint was progression-free survival, assessed every 6 weeks, to validate the predictive value of the TrPAL biomarker. If patients with TrPAL values of less than or equal to the ULN had a Bayesian probability of more than 95% that the true hazard ratio (HR) for progression-free survival was less than 1, and if those with TrPAL values of greater than the ULN had a probability of more than 80% that the true HR for progression-free survival was more than 1, the TrPAL biomarker would be validated. We did primary analyses in the intention-to-treat population and safety analyses in those who had received at least one dose of study drug and had at least one valid post-baseline safety assessment. Monitors, site staff, and patients are still masked to treatment assignment. This trial is registered with ClinicalTrials.gov, number NCT01383148.

Findings: Between April 10, 2012, and Sept 12, 2014, we randomly allocated 222 patients (TG4010 and chemotherapy 111 [50%]; placebo and chemotherapy 111 [50%]). In the whole population, median progression-free survival was 5·9 months (95% CI 5·4–6·7) in the TG4010 group and 5·1 months (4·2–5·9) in the placebo group (HR 0·74 [95% CI 0·55–0·98]; one-sided p=0·019). In patients with TrPAL values of less than or equal to the ULN, the HR for progression-free survival was 0·75 (0·54–1·03); the posterior probability of the HR being less than 1 was 98·4%, and thus the primary endpoint was met. In patients with TrPAL values of greater than the ULN, the HR for progression-free survival was 0·77 (0·42–1·40); the posterior probability of the HR being greater than 1 was 31·3%, and the primary endpoint was not met. We noted grade 1–2 injection-site reactions in 36 (33%) of 110 patients in the TG4010 group versus four (4%) of 107 patients in the placebo group. We noted no grade 3 or 4 nor serious adverse events deemed to be related to TG4010 only. Four (4%) patients presented grade 3 or 4 adverse events related to TG4010 and other study treatments (chemotherapy or bevacizumab) versus 11 (10%) in the placebo group. No serious adverse event was related to the combination of TG4010 with other study treatments. The most frequent severe adverse events were neutropenia (grade 3 29 [26%], grade 4 13 [12%] in the TG4010 group vs grade 3 22 [21%], grade 4 11 [10%] in the placebo group), anaemia (grade 3 12 [11%] vs grade 3 16 [15%]), and fatigue (grade 3 12 [11%], grade 5 one [1%] vs grade 3 13 [12%]; no grade 4 events).

Interpretation: TG4010 plus chemotherapy seems to improve progression-free survival relative to placebo plus chemotherapy. These data support the clinical value of the TrPAL biomarker in this clinical setting; because the primary endpoint was met, the trial is to continue into the phase 3 part.

Funding: Transgene, Avancées Diagnostiques pour de Nouvelles Approches Thérapeutiques (ADNA), and OSEO.
212-223
Quoix, Elisabeth
44ebb87a-caa7-4b13-844d-a6d4c99843a5
Lena, Hervé
baf03d34-bae5-4fa7-bc28-072d112060d6
Losonczy, Gyorgy
1c95912b-7375-442e-8103-ba1168c07d4a
Forget, Frédéric
5b544c2a-f8e8-4b45-b024-6c3a22dede30
Chouaid, Christos
ec00ebb7-47db-4693-aa21-8c6f24a7d0a0
Papai, Zsolt
a76040be-6c56-4552-8478-9eb8baa455c8
Gervais, Radj
5d926421-4274-49e6-93f0-946ab5907807
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
Szczesna, Aleksandra
754ea18d-5255-4f76-9440-7cb8a24bd9a0
Kazarnowicz, Andrzej
f092fdd1-268c-48b3-afe7-03cbc6523af2
Beck, Joseph T.
50c3aba6-e45a-488c-bbf2-7d77c4b4c6c2
Westeel, Virginie
ffc9150d-9f9d-4944-bad9-090678ccbcc7
Felip, Enriqueta
e1c9cb6c-4e62-4a7e-aec6-2c24994738db
Debieuvre, Didier
84af928e-3762-4ad8-ab66-c61ea8aa4741
Madroszyk, Anne
f5f33fe2-dc51-41bc-bb0a-f8c3f7a480f3
Adam, Julien
24c965b9-99b2-468b-aeab-8be64a264fcf
Lacoste, Gisèle
8da4ae98-e6e7-4092-a883-02d8dd712afb
Tavernaro, Annette
b5337d8e-b452-45bb-a323-4c7df2cf97f2
Bastien, Bérangère
b62db35a-03aa-45e4-be1b-22fb8323924e
Halluard, Céline
6952f488-946f-457e-a48d-2b12de499f49
Palanché, Tania
b668aea6-b542-4a9b-be61-0f65eb356b74
Limacher, Jean-Marc
33d9099a-2a59-4bd7-9fa8-5bead11aea52
Quoix, Elisabeth
44ebb87a-caa7-4b13-844d-a6d4c99843a5
Lena, Hervé
baf03d34-bae5-4fa7-bc28-072d112060d6
Losonczy, Gyorgy
1c95912b-7375-442e-8103-ba1168c07d4a
Forget, Frédéric
5b544c2a-f8e8-4b45-b024-6c3a22dede30
Chouaid, Christos
ec00ebb7-47db-4693-aa21-8c6f24a7d0a0
Papai, Zsolt
a76040be-6c56-4552-8478-9eb8baa455c8
Gervais, Radj
5d926421-4274-49e6-93f0-946ab5907807
Ottensmeier, Christian
42b8a398-baac-4843-a3d6-056225675797
Szczesna, Aleksandra
754ea18d-5255-4f76-9440-7cb8a24bd9a0
Kazarnowicz, Andrzej
f092fdd1-268c-48b3-afe7-03cbc6523af2
Beck, Joseph T.
50c3aba6-e45a-488c-bbf2-7d77c4b4c6c2
Westeel, Virginie
ffc9150d-9f9d-4944-bad9-090678ccbcc7
Felip, Enriqueta
e1c9cb6c-4e62-4a7e-aec6-2c24994738db
Debieuvre, Didier
84af928e-3762-4ad8-ab66-c61ea8aa4741
Madroszyk, Anne
f5f33fe2-dc51-41bc-bb0a-f8c3f7a480f3
Adam, Julien
24c965b9-99b2-468b-aeab-8be64a264fcf
Lacoste, Gisèle
8da4ae98-e6e7-4092-a883-02d8dd712afb
Tavernaro, Annette
b5337d8e-b452-45bb-a323-4c7df2cf97f2
Bastien, Bérangère
b62db35a-03aa-45e4-be1b-22fb8323924e
Halluard, Céline
6952f488-946f-457e-a48d-2b12de499f49
Palanché, Tania
b668aea6-b542-4a9b-be61-0f65eb356b74
Limacher, Jean-Marc
33d9099a-2a59-4bd7-9fa8-5bead11aea52

Quoix, Elisabeth, Lena, Hervé, Losonczy, Gyorgy, Forget, Frédéric, Chouaid, Christos, Papai, Zsolt, Gervais, Radj, Ottensmeier, Christian, Szczesna, Aleksandra, Kazarnowicz, Andrzej, Beck, Joseph T., Westeel, Virginie, Felip, Enriqueta, Debieuvre, Didier, Madroszyk, Anne, Adam, Julien, Lacoste, Gisèle, Tavernaro, Annette, Bastien, Bérangère, Halluard, Céline, Palanché, Tania and Limacher, Jean-Marc (2016) TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial. Lancet Oncology, 17 (2), 212-223. (doi:10.1016/S1470-2045(15)00483-0). (PMID:26727163)

Record type: Article

Abstract

Background: MUC1 is a tumour-associated antigen expressed by many solid tumours, including non-small-cell lung cancer. TG4010 is a modified vaccinia Ankara expressing MUC1 and interleukin 2. In a previous study, TG4010 combined with chemotherapy showed activity in non-small-cell lung cancer and the baseline value of CD16, CD56, CD69 triple-positive activated lymphocytes (TrPAL) was shown to be potentially predictive of TG4010 efficacy. In this phase 2b part of the phase 2b/3 TIME trial, we further assess TG4010 in combination with first-line chemotherapy and use of the TrPAL biomarker in this setting.

Methods: In this phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial, we recruited previously untreated patients aged 18 years or older with stage IV non-small-cell lung cancer without a known activating EGFR mutation and with MUC1 expression in at least 50% of tumoural cells. Patients were randomly allocated (1:1) by an external service provider to subcutaneous injections of 108 plaque-forming units of TG4010 or placebo from the beginning of chemotherapy every week for 6 weeks and then every 3 weeks up to progression, discontinuation for any reason, or toxic effects, stratified according to baseline value of TrPAL (? or > the upper limit of normal [ULN]) and, in addition, a dynamic minimisation procedure was used, taking into account chemotherapy regimen, histology, addition or not of bevacizumab, performance status, and centre. Patients, site staff, monitors, the study funder, data managers, and the statistician were masked to treatment identity. The primary endpoint was progression-free survival, assessed every 6 weeks, to validate the predictive value of the TrPAL biomarker. If patients with TrPAL values of less than or equal to the ULN had a Bayesian probability of more than 95% that the true hazard ratio (HR) for progression-free survival was less than 1, and if those with TrPAL values of greater than the ULN had a probability of more than 80% that the true HR for progression-free survival was more than 1, the TrPAL biomarker would be validated. We did primary analyses in the intention-to-treat population and safety analyses in those who had received at least one dose of study drug and had at least one valid post-baseline safety assessment. Monitors, site staff, and patients are still masked to treatment assignment. This trial is registered with ClinicalTrials.gov, number NCT01383148.

Findings: Between April 10, 2012, and Sept 12, 2014, we randomly allocated 222 patients (TG4010 and chemotherapy 111 [50%]; placebo and chemotherapy 111 [50%]). In the whole population, median progression-free survival was 5·9 months (95% CI 5·4–6·7) in the TG4010 group and 5·1 months (4·2–5·9) in the placebo group (HR 0·74 [95% CI 0·55–0·98]; one-sided p=0·019). In patients with TrPAL values of less than or equal to the ULN, the HR for progression-free survival was 0·75 (0·54–1·03); the posterior probability of the HR being less than 1 was 98·4%, and thus the primary endpoint was met. In patients with TrPAL values of greater than the ULN, the HR for progression-free survival was 0·77 (0·42–1·40); the posterior probability of the HR being greater than 1 was 31·3%, and the primary endpoint was not met. We noted grade 1–2 injection-site reactions in 36 (33%) of 110 patients in the TG4010 group versus four (4%) of 107 patients in the placebo group. We noted no grade 3 or 4 nor serious adverse events deemed to be related to TG4010 only. Four (4%) patients presented grade 3 or 4 adverse events related to TG4010 and other study treatments (chemotherapy or bevacizumab) versus 11 (10%) in the placebo group. No serious adverse event was related to the combination of TG4010 with other study treatments. The most frequent severe adverse events were neutropenia (grade 3 29 [26%], grade 4 13 [12%] in the TG4010 group vs grade 3 22 [21%], grade 4 11 [10%] in the placebo group), anaemia (grade 3 12 [11%] vs grade 3 16 [15%]), and fatigue (grade 3 12 [11%], grade 5 one [1%] vs grade 3 13 [12%]; no grade 4 events).

Interpretation: TG4010 plus chemotherapy seems to improve progression-free survival relative to placebo plus chemotherapy. These data support the clinical value of the TrPAL biomarker in this clinical setting; because the primary endpoint was met, the trial is to continue into the phase 3 part.

Funding: Transgene, Avancées Diagnostiques pour de Nouvelles Approches Thérapeutiques (ADNA), and OSEO.

Text
Quoix -TG4010 Lancet Oncology 2015.pdf - Version of Record
Restricted to Repository staff only
Request a copy

More information

e-pub ahead of print date: 23 December 2015
Published date: February 2016
Organisations: Cancer Sciences

Identifiers

Local EPrints ID: 396146
URI: http://eprints.soton.ac.uk/id/eprint/396146
PURE UUID: 85198d0f-b356-4e5a-a482-6fa11168e5f3

Catalogue record

Date deposited: 07 Jun 2016 08:48
Last modified: 16 Dec 2019 19:53

Export record

Altmetrics

Contributors

Author: Elisabeth Quoix
Author: Hervé Lena
Author: Gyorgy Losonczy
Author: Frédéric Forget
Author: Christos Chouaid
Author: Zsolt Papai
Author: Radj Gervais
Author: Aleksandra Szczesna
Author: Andrzej Kazarnowicz
Author: Joseph T. Beck
Author: Virginie Westeel
Author: Enriqueta Felip
Author: Didier Debieuvre
Author: Anne Madroszyk
Author: Julien Adam
Author: Gisèle Lacoste
Author: Annette Tavernaro
Author: Bérangère Bastien
Author: Céline Halluard
Author: Tania Palanché
Author: Jean-Marc Limacher

University divisions

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×